Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) PT at $8.18

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.18.

A number of equities analysts have issued reports on GDRX shares. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. KeyCorp lowered their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Wells Fargo & Company lowered their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Citigroup lowered their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a report on Friday, January 10th. Finally, Barclays lowered their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th.

Hedge Funds Weigh In On GoodRx

Hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new position in GoodRx during the third quarter worth about $11,295,000. Clearbridge Investments LLC bought a new position in GoodRx during the fourth quarter worth about $5,863,000. Rubric Capital Management LP grew its holdings in GoodRx by 25.2% during the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after purchasing an additional 943,226 shares during the period. Franklin Resources Inc. bought a new position in GoodRx during the third quarter worth about $5,675,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in GoodRx by 303.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock worth $4,936,000 after purchasing an additional 798,261 shares during the period. Institutional investors own 63.77% of the company’s stock.

GoodRx Price Performance

GDRX stock opened at $4.61 on Friday. The stock has a 50-day moving average price of $4.73 and a two-hundred day moving average price of $5.64. The stock has a market cap of $1.76 billion, a PE ratio of -153.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 1 year low of $4.09 and a 1 year high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.